This inventor holds 2 USPTO granted patents and 12 published patent applications, plus 1 CIPO patent. Top assignee: Immunicom, Inc.. Active years: 2021-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- San Diego, CA (US) (2021)
- San Dieog, CA (US) (2023)
Company Filing History:
Years Active: 2021-2023
Title: Innovations by Robert Segal in Cancer Treatment
Introduction
Robert Segal is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of cancer treatment through his innovative patents. With a total of 2 patents, Segal's work focuses on enhancing the efficacy of immune checkpoint inhibitors.
Latest Patents
One of Segal's latest patents is titled "Increasing responses to checkpoint inhibitors by extracorporeal apheresis." This invention provides means, methods, and compositions of matter useful for enhancing tumor response to checkpoint inhibitors. In one embodiment, the invention teaches the utilization of extracorporeal apheresis, specifically the removal of various tumor-derived or tumor microenvironment-derived immunological 'blocking factors.' The invention also provides the removal of soluble TNF-alpha receptors (sTNF-Rs) as a means of augmenting the efficacy of immune checkpoint inhibitors. In a specific embodiment, the removal of sTNF-Rs is utilized to enhance the efficacy of inhibitors of the PD-1/PD-L1 pathway and/or the CD28/CTLA-4 pathway.
Another significant patent by Segal is the "System and method for removal of immune inhibitors from biological fluids." This system and method are useful for the removal of immune inhibitors such as soluble TNF receptors from the body fluid of cancer patients. In some embodiments, soluble TNF-Receptors 1 and 2 are selectively removed from plasma at 80% or more efficiency. The system includes an immobilized capture ligand of a single chain TNF-α. This invention is beneficial for the treatment of different cancer types, stages, and severity.
Career Highlights
Robert Segal is currently associated with Immunicom, Inc., where he continues to develop innovative solutions for cancer treatment. His work has garnered attention for its potential to improve patient outcomes in oncology.
Collaborations
Segal collaborates with notable professionals in the field, including Steven Francis Josephs and Stephen Michael Prince. Their combined expertise contributes to the advancement of cancer treatment technologies.
Conclusion
Robert Segal's innovative patents represent significant advancements in cancer treatment, particularly in enhancing the efficacy of immune checkpoint inhibitors. His work continues to pave the way for improved therapeutic strategies in oncology.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile